Drug Discovery Today - Biotherapeutics

Latest News

CRT and Bayer Schering Pharma to investigate gynaecological and oncological diseases
Cancer Research Technology has signed an agreement with Bayer Schering Pharma AG, Germany, to evaluate new leptin antagonist peptides as potential experimental treatments, initially in the area of gynaecological diseases, including cancer.
Body clock drugs could ease psychiatric disorders
Researchers have used a drug to reset and restart the 24 hour body clock of mice, which could eventually help with human difficulties including some psychiatric disorders, jet lag and the health impacts of shift work.
CRT and ValiRx sign prostate cancer treatment deal
Cancer Research Technology has signed a deal to provide biotech company ValiRx PLC with the global rights to develop a promising compound to treat hormone-resistant prostate cancer.
Antiviral effective in clinical trial for common cold
A pilot clinical trial examining Marinomed’s antiviral nasal spray, which contains carrageenan, has indicated that it is effective as a treatment against the common cold.
Results of research on aurora kinase inhibitors announced
BICOLL GmbH and EMBL have announced the successful completion of a joint research project on the identification of active compounds as inhibitors of aurora kinases.

Podcasts

Evotec strengthens and expands its Alliance Business
Dr Mark Ashton is Executive Vice President, Business Development of Evotec and is responsible for Evotec's commercial and partnering activities. Prior to assuming responsibility for Business Development in 2005, Dr Ashton held a number of positions within Operations at Evotec: He joined the Company in 1995 as one of the initial employees of the Discovery Division, becoming Department Manager in 2001, Director of Chemistry Services in 2002 and taking over responsibility for Evotec's Discovery Services Division in 2004, where he had responsibility for Evotec's screening, parallel synthesis and medicinal chemistry operations. During his time at Evotec, Dr Ashton has managed a wide range of pharmaceutical and biotechnology related projects, including medicinal chemistry projects, design and synthesis of screening libraries and technology transfer projects and has been involved in the progression of a number of drug candidates into the clinic in numerous therapeutic areas. Dr Ashton has authored and co-authored a number of peer reviewed papers, articles and book chapters in addition to being named on a number of pharmaceutical patents. He is trained as a medicinal chemist. Prior to joining Evotec, Dr Ashton also had spells at ICI Pharmaceuticals and Organon Laboratories. Mark Whittaker is Senior Vice President Drug Discovery at Evotec where he manages a large drug discovery collaboration and the groups of computational chemistry and structural biology. Before joining Evotec in 2001, Mark spent 13 years at British Biotech Pharmaceuticals where he led a number of medicinal chemistry programmes and was latterly Director of Chemistry. At British Biotech, Mark contributed to the discovery and development of six compounds that have progressed into human clinical trials. Before his career at British Biotech, Mark carried out post-doctoral research at the University of Oxford and at York University, Toronto and obtained a D. Phil in Chemistry from the University of York.
The Ubiquitin Story
In this podcast interview with Drug Discovery Today, Nobel Prize winner Professor Aaron Ciechanover will talk about his career, his Nobel Prize-winning discovery of the UPS, and the extraordinary opportunities and challenges for drug discovery in this area.
Califf, Behrman and Kramer discuss the Clinical Trials Transformation Initiative.
Download the Califf, Behrman and Kramer podcast as an mp3 file
Dr Brent Vose outlines AstraZeneca's oncology pipeline.
Download the Dr. Brent Vose podcast as an mp3 file

Webinars

The renaissance of clinical biochemistry: Diagnostic biomarker discovery by targeted metabolomics
Metabolomics, i.e. the systematic identification and quantitation of marker metabolites in a given compartment, cell, tissue or body fluid, is increasingly recognized as the most relevant approach to depicting the functional end-points of physiological and pathophysiological processes. Yet, a reliable and standardized technology platform rendering metabolomics applicable to routine diagnostics has not been in place so far.
Aequorin Bioluminescence Assays – a paradigm shift?
Metabolomics, a Novel Tool for Understanding the Early-Stage Mechanistic Underpinnings of Drug Action and Safety.
In association with Matabolon. This presentation demonstrated the utility of metabolomics in drug safety research through a case study done in collaboration with Teva Pharmaceutical Industries Ltd.

Downloads

Non-coding RNAs and new opportunities for the private sector
Fabrício F. Costa argues that the private sector should start paying more attention to non-coding RNAs to improve the pipeline for drug discovery and drug development and to facilitate the identification of new diagnostic and prognostic markers.
Targeted genetic and viral therapy for advanced head and neck cancers
Head and neck cancers usually present with advanced disease, and novel therapies are urgently needed. Here, Pin-I Huang, Ju-Fang Chang, David H. Kirn and Ta-Chiang Liu summarize the available clinical data and discuss challenges and future directions.
siRNAs: their potential as therapeutic agents – Part II. Methods of delivery
Sunit Kumar Singh and Praveensingh B. Hajeri discuss the challenges associated with siRNA and the full potential of RNAi for the development of therapeutic tools and drugs.
siRNAs: their potential as therapeutic agents – Part I. Designing of siRNAs
Developing precise tools for designing siRNAs can achieve the most efficient knockdown of target genes and reduce off-target effects. Here, Praveensingh B. Hajeri and Sunit Kumar Singh discuss the strategies and parameters required for effective siRNA designing and synthesis.

25 Hottest Articles

Pharmacophore modeling and applications in drug discovery: challenges and recent advances • Review article
Drug Discovery Today, Volume 15, Issue 11-12, June 2010, Pages 444-450 | Yang, S.Y.
The road ahead for large pharma: long-term science and innovation • Editorial
Drug Discovery Today, Volume 14, Issue 9-10, May 2009, Pages 439-441 | Lundberg, J.M.; Reilly, C.
The growing impact of click chemistry on drug discovery • Review article
Drug Discovery Today, Volume 8, Issue 24, December 2003, Pages 1128-1137 | Kolb, H.C.; Sharpless, K.B.
Drug discovery chemistry: a primer for the non-specialist • Review article
Drug Discovery Today, Volume 14, Issue 15-16, August 2009, Pages 731-744 | Jordan, A.M.; Roughley, S.D.
Text-based knowledge discovery: search and mining of life-sciences documents • Review article
Drug Discovery Today, Volume 7, Issue 11, May 2002, Pages S89-S98 | Mack, R.; Hehenberger, M.

Latest News

Podcasts

Webinars

Downloads

25 Hottest Articles

Filter Content by geographic state

Select a state by clicking...

select a state:
		Current state : Not selected.

Latest News

Podcasts

Webinars

Downloads

25 Hottest Articles

Members' Login

Not a member?

Filter Content by geographic state

Select a state by clicking...